BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

Haematologica. 2018 Jan;103(1):e10-e12. doi: 10.3324/haematol.2017.176347. Epub 2017 Oct 5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Amino Acid Substitution
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm / genetics
  • Fusion Proteins, bcr-abl / genetics*
  • Gene Expression
  • Humans
  • Imidazoles / pharmacology*
  • Imidazoles / therapeutic use
  • Mutation*
  • Pharmacogenomic Testing
  • Pharmacogenomic Variants*
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridazines / pharmacology*
  • Pyridazines / therapeutic use

Substances

  • Antineoplastic Agents
  • BCR-ABL1 fusion protein, human
  • Imidazoles
  • Protein Kinase Inhibitors
  • Pyridazines
  • ponatinib
  • Fusion Proteins, bcr-abl